post acute coronary syndromes clinical trials results

dabigatran versus placebo
REDEEM, 2009
NCT00621855
dabigatran 4 dosages (50mg twice daily, 75mg twice daily, 110mg twice daily, 150mg twice daily)
versus
placebo
patients with recent acute coronary syndromes (ST- or non-ST-elevation myocardical infarction)double blind
Follow-up duration: 6 months
succinobucol versus placebo
ARISE, 2007
NCT00066898
succinobucol (300 mg/day)
versus
placebo
high-risk patients with recent acute coronary syndrome Double blind
Follow-up duration: 24 months mean
canada, US, UK, South Africa